RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2014; 112(06): 1077-1078
DOI: 10.1160/th14-08-0702
DOI: 10.1160/th14-08-0702
Invited Editorial Focus
Can we improve the efficacy of low-dose aspirin?
Authors
Weitere Informationen
Publikationsverlauf
Received:
05. August 2014
Accepted:
25. August 2014
Publikationsdatum:
17. November 2017 (online)
Editorial Focus on Bonten et al. Thromb Haemost 2014; 112: 1209-1218.
-
References
- 1 Bonten TN, Oostrom M, Snoep J. et al. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity: A randomised crossover trial. Thromb Haemost 2014; 112: 1209-1218.
- 2 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-1372.
- 3 Halvorsen S, Andreotti F, ten Berg JM. et al. Aspirin Therapy in Primary Cardiovascular Disease Prevention: A Position Paper of the European Society of Cardiology Working Group on Thrombosis. J Am Coll Cardiol 2014; 64: 319-327.
- 4 Patrono C, Andreotti F, Arnesen H. et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922-2932.
- 5 Cohen MC, Rohtla KM, Lavery CE. et al. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997; 79: 1512-1516.
- 6 Mogabgab O, Giugliano RP, Sabatine MS. et al. Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int 2012; 29: 1390-1396.
- 7 Tofler GH, Brezinski D, Schafer AI. et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316: 1514-1518.
- 8 Scheer FA, Michelson AD, Frelinger III AL. et al. The Human Endogenous Circadian System Causes Greatest Platelet Activation during the Biological Morning Independent of Behaviors. PLoS One 2011; 06: e24549.
- 9 Dalby MC, Davidson SJ, Burman JF. et al. Diurnal variation in platelet aggregation iwth the PFA-100 platelet function analyser. Platelets 2000; 11: 320-324.
- 10 Henry P, Vermillet A, Boval B. et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2010; 105: 336-344.
- 11 Christensen KH, Grove EL, Wurtz M. et al. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Platelets. 2014 Epub ahead of print.
- 12 Wurtz M, Hvas AM, Jensen LO. et al. 24-hour anti-platelet effect of aspirin in patients with previous definite stent thrombosis. Int J Cardiol 2014; 175: 274-279.
- 13 Moore JG, Goo RH. Day and night aspirin-induced gastric mucosal damage and protection by ranitidine in man. Chronobiol Int 1987; 04: 111-116.
- 14 Cea Soriano L, Bueno H, Lanas A. et al. Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation. Thromb Haemost 2013; 110: 1298-1304.
- 15 Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 2012; 18: 5344-5361.
- 16 Martin JF, Kristensen SD, Mathur A. et al. The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol 2012; 09: 658-670.
- 17 Di MG, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61: 1081-1085.
- 18 FitzGerald GA, Brash AR, Oates JA. et al. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest 1983; 72: 1336-1343.
- 19 Rocca B, Santilli F, Pitocco D. et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10: 1220-1230.
- 20 Pascale S, Petrucci G, Dragani A. et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119: 3595-3603.
- 21 Grove EL, Hvas AM, Mortensen SB. et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 09: 185-191.
- 22 Perneby C, Wallen NH, Rooney C. et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-658.
- 23 Capodanno D, Patel A, Dharmashankar K. et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011; 04: 180-187.
- 24 Lordkipanidze M, Harrison P. Aspirin twice a day keeps new COX-1 at bay. J Thromb Haemost 2012; 10: 1217-1219.
- 25 Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101: 151-156.
- 26 Ridker PM, Manson JE, Buring JE. et al. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 1990; 82: 897-902.